AP1S2

Across TCGA pan-cancer cohorts, AP1S2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AP1S2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AP1S2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AP1S2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, STAD, and CESC are the cancer types where AP1S2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	36	view →
STAD	OS	Median	All	0.075	0.667	<.001	30	view →
CESC	OS	Median	All	0.203	0.798	.002	18	view →
ESCA	OS	Median	All	0.211	0.700	.020	9	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.028	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AP1S2–BLCA (OS)

Open the BLCA breakdown →